Effect of ticagrelor with or without aspirin on vein graft outcome 1 year after on-pump and off-pump coronary artery bypass grafting
| العنوان: | Effect of ticagrelor with or without aspirin on vein graft outcome 1 year after on-pump and off-pump coronary artery bypass grafting |
|---|---|
| المؤلفون: | Rui Wang, Minlu Zhang, Hao Liu, Xiaowei Wang, Qiang Zhao, Junlong Hu, Qing Xue, Lin Han, Yunpeng Zhu |
| المصدر: | J Thorac Dis |
| بيانات النشر: | AME Publishing Company, 2020. |
| سنة النشر: | 2020 |
| مصطلحات موضوعية: | Pulmonary and Respiratory Medicine, medicine.medical_specialty, Aspirin, Bypass grafting, business.industry, medicine.medical_treatment, Vein graft, 030204 cardiovascular system & hematology, law.invention, Surgery, 03 medical and health sciences, surgical procedures, operative, 0302 clinical medicine, medicine.anatomical_structure, law, Post-hoc analysis, medicine, Cardiopulmonary bypass, Original Article, 030212 general & internal medicine, business, Ticagrelor, Off-pump coronary artery bypass, medicine.drug, Artery |
| الوصف: | Background In the present post hoc analysis of the DACAB trial, we evaluated the effects of ticagrelor with or without aspirin on 1-year vein graft outcomes after coronary artery bypass grafting (CABG) with and without cardiopulmonary bypass (CPB) (on-pump and off-pump). Methods The DACAB trial was a multicenter, randomized, open-label, parallel control study enrolling 500 patients with 1,460 vein grafts undergoing CABG. For current post-hoc study, all patients in the DACAB study were included in the analysis to compare the effects of different antiplatelet regimens under on/off pump. Patients were randomly assigned to 1 of 3 antiplatelet treatment regimens (ticagrelor plus aspirin, T + A; ticagrelor alone, T; or aspirin alone, A) within 24 hours after CABG, and were stratified into on-pump and off-pump subgroups. The primary outcome was 1-year vein graft patency rate. Results Totally 121 patients underwent on-pump CABG (39 with 121 vein grafts in T + A, 36 with 101 vein grafts in T, and 46 with 137 vein grafts in A) and 379 patients underwent off-pump CABG (129 with 336 vein grafts in T + A, 130 with 387 vein grafts in T, and 120 with 348 vein grafts in A). Compared with A, T + A showed a higher 1-year vein graft patency rate in both on-pump (adjusted OR for non-patency =0.62, 95% CI: 0.16-2.45) and off-pump (adjusted OR for non-patency =0.35, 95% CI: 0.20-0.62) subgroups, P interaction =0.647; whereas T did not in either on-pump (adjusted OR for non-patency = 0.92, 95% CI: 0.31-2.76) or off-pump (adjusted OR for non-patency =0.58, 95% CI: 0.34-1.00) subgroups, P interaction =0.430. Conclusions In the DACAB trial, for patients underwent either on-pump or off-pump CABG, ticagrelor plus aspirin showed consistent benefit for achieving 1-year vein graft patency, with particular benefit being seen in the off-pump. |
| تدمد: | 2077-6624 2072-1439 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::efd9bf83b7a8122ce3968798331748d2Test https://doi.org/10.21037/jtd-20-1177Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....efd9bf83b7a8122ce3968798331748d2 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 20776624 20721439 |
|---|